MetaCap

Insmed Incorporated (INSM)

NASDAQ: INSMHealth CareBiotechnology: Pharmaceutical PreparationsUSD

141.33-3.13 (-2.17%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

INSM stock chart

Technical analysis

Key statistics

All statistics
Market cap
$31.01B
EPS (TTM)
-$2.81
52-week range
90.39 – 212.75
Day range
140.99 – 150.00
Volume / Avg
6.22M / 3.09M
Beta
—

52-week range

$90.39$212.75

INSM stock today

Shares of Insmed (INSM) finished lower on Nov 20 at $141.33, a drop of 2.17% or $3.13 per share, versus the S&P 500's 3.70% decline. Volume was 2.0x the average at 6.22M shares, a sign of unusually heavy trading. Shares are 33.6% below their 52-week high of $212.75, set on Dec 2, 2025 and 56.4% above the 52-week low of $90.39, in the middle of the past year's range.

INSM is down 18.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 28.9%. Insmed has posted a net loss over the last twelve months (EPS of -$2.81), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Insmed

Company profile

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. William H. Lewis J.D., M.B.A.
Headquarters
Bridgewater, NJ
Employees
1,664
Website
insmed.com

Financial highlights

Full financials

In fiscal 2025, Insmed generated $606.4 million in revenue, up 66.7% from fiscal 2024, its 8th consecutive year of revenue growth. Insmed reported a net loss of $1.28 billion, compared with a loss of $913.8 million a year earlier. Gross margin was 79.7% (up from 76.4%) and operating margin -205.6%.

Insmed annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$606.42M$363.71M$305.21M$245.36M$188.46M
Growth+66.73%+19.17%+24.39%+30.19%+14.63%
Net income$-1.28B$-913.77M$-749.57M$-481.53M$-434.65M
EPS (diluted)$-6.42$-5.57$-5.34$-3.91$-3.88

Analyst forecast

Forecast

Consensus (24 analysts)

strong_buy

Avg. price target

$194.18+37.39%

  • Strong buy 5
  • Buy 18
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $158.00High $243.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 29, 2026
EPS actual vs est.
$-0.46 vs $-0.34
Surprise
-35.29%

INSM news

All INSM news

Insmed peers

Health Care sector
INSM peer companies
CompanyPrice% ChgMarket capCompare
GMABGenmab A/S ADS50.60-1.46%$31.20Bvs INSM
ZTSZoetis Inc. Class A79.11-2.08%$32.14Bvs INSM
ROIVRoivant Sciences Ltd.38.66-0.78%$28.01Bvs INSM
UTHRUnited Therapeutics Corporation554.73-0.78%$23.63Bvs INSM
RPRXRoyalty Pharma plc Class A68.45+1.08%$39.36Bvs INSM
VTRSViatris Inc.19.63-1.26%$22.50Bvs INSM
ALNYAlnylam Pharmaceuticals Inc.143.82-2.71%$19.26Bvs INSM
ONCBeOne Medicines Ltd. ADR390.94-2.19%$44.66Bvs INSM

Indexes, lists and sector

Insmed stock FAQ

What is Insmed's stock price today?

INSM last traded at $141.33 as of Nov 20, 4:00 PM EST, down 2.17% on the day. Prices are delayed at least 15 minutes.

Does Insmed pay a dividend?

No. Insmed does not currently pay a regular cash dividend.

Who is Insmed's CEO?

Mr. William H. Lewis J.D., M.B.A. is the chief executive officer of Insmed Incorporated, which has about 1,664 employees.

Has INSM ever split its stock?

Yes. The most recent INSM stock split was a 1-for-10 split on Mar 3, 2011, one of 2 splits on record.

What is the INSM 52-week high?

The 52-week high for INSM is $212.75 and the 52-week low is $90.39. The stock is currently 33.6% below its high.

Compare INSM